Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
Alterity Therapeutics (NASDAQ: ATHE) presented new data on ATH434 at the Society for Neuroscience 2024 in Chicago. The poster, titled 'Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of α-Synuclein Aggregation with Moderate Iron-binding Affinity,' showcased ATH434's neuroprotective and mitochondrial protectant properties, including reducing lipid damage in two neuronal injury models.
The study, led by Dr. Daniel J. Kosman at SUNY Buffalo, demonstrated ATH434's intrinsic antioxidant activity and its ability to redistribute excess labile iron. These properties suggest potential for treating neurodegenerative diseases like Parkinson's. ATH434 also promoted energy production in mitochondria through a pathway less prone to causing oxidative stress in unstressed cells.
Dr. David Stamler, CEO of Alterity, emphasized the importance of these findings in understanding ATH434's potential as a disease-modifying treatment for neurodegenerative disorders.
Alterity Therapeutics (NASDAQ: ATHE) ha presentato nuovi dati su ATH434 alla Society for Neuroscience 2024 a Chicago. Il poster, intitolato 'Effetti Antiossidanti Potenti e Protettivi per i Mitocondri di ATH434, un Nuovo Inibitore dell'Agraggamento di α-Sinucleina con Affinità Moderata per il Ferro,' ha messo in luce le proprietà neuroprotettive e protettive per i mitocondri di ATH434, inclusa la riduzione del danno lipidico in due modelli di lesione neuronale.
Lo studio, guidato dal Dr. Daniel J. Kosman della SUNY Buffalo, ha dimostrato l'attività antiossidante intrinseca di ATH434 e la sua capacità di redistribuire il ferro labile in eccesso. Queste proprietà suggeriscono un potenziale per il trattamento di malattie neurodegenerative come il Parkinson. ATH434 ha anche promosso la produzione di energia nei mitocondri attraverso una via meno soggetta a causare stress ossidativo in cellule non stressate.
Il Dr. David Stamler, CEO di Alterity, ha enfatizzato l'importanza di questi risultati nella comprensione del potenziale di ATH434 come trattamento modificante la malattia per i disturbi neurodegenerativi.
Alterity Therapeutics (NASDAQ: ATHE) presentó nuevos datos sobre ATH434 en la Society for Neuroscience 2024 en Chicago. El póster, titulado 'Efectos Antioxidantes Potentes y Protectores Mitocondriales de ATH434, un Nuevo Inhibidor de la Agregación de α-Sinucleína con Afinidad Moderada por el Hierro,' mostró las propiedades neuroprotectoras y protectoras mitocondriales de ATH434, incluyendo la reducción del daño lipídico en dos modelos de lesión neuronal.
El estudio, liderado por el Dr. Daniel J. Kosman de SUNY Buffalo, demostró la actividad antioxidante intrínseca de ATH434 y su capacidad para redistribuir el exceso de hierro lábil. Estas propiedades sugieren un potencial para tratar enfermedades neurodegenerativas como el Parkinson. ATH434 también promovió la producción de energía en mitocondrias a través de una vía menos propensa a causar estrés oxidativo en células no estresadas.
El Dr. David Stamler, CEO de Alterity, enfatizó la importancia de estos hallazgos para comprender el potencial de ATH434 como un tratamiento modificador de la enfermedad para trastornos neurodegenerativos.
Alterity Therapeutics (NASDAQ: ATHE)은 시카고에서 열린 2024년 신경과학 학회에서 ATH434에 대한 새로운 데이터를 발표했습니다. 'α-시뉴클레인 응집 억제제인 ATH434의 강력한 항산화 및 미토콘드리아 보호 효과'라는 제목의 포스터에서는 두 개의 신경 손상 모델에서 지질 손상을 줄이는 것을 포함하여 ATH434의 신경 보호 및 미토콘드리아 보호 특성을 소개했습니다.
SUNY 버팔로의 Daniel J. Kosman 박사가 이끈 연구는 ATH434의 고유한 항산화 활성과 과도한 불안정한 철을 재분배하는 능력을 입증했습니다. 이러한 특성은 파킨슨병과 같은 신경퇴행성 질환 치료의 가능성을 제시합니다. ATH434는 또한 스트레스가 없는 세포에서 산화 스트레스를 유발할 가능성이 낮은 경로를 통해 미토콘드리아에서 에너지 생산을 촉진했습니다.
Alterity의 CEO인 David Stamler 박사는 신경퇴행성 질환에 대한 병변 수정 치료제로서 ATH434의 가능성을 이해하는 데 있어 이러한 발견의 중요성을 강조했습니다.
Alterity Therapeutics (NASDAQ: ATHE) a présenté de nouvelles données sur ATH434 lors de la Society for Neuroscience 2024 à Chicago. L'affiche, intitulée 'Effets Antioxydants Puissants et Protecteurs des Mitochondries d'ATH434, un Inhibiteur Novateur de l'Aggrégation de l'α-Synucléine avec Affinité Modérée pour le Fer,' a mis en avant les propriétés neuroprotectrices et protectrices des mitochondries d'ATH434, y compris la réduction des dommages lipidiques dans deux modèles de lésions neuronales.
L'étude, dirigée par le Dr. Daniel J. Kosman de SUNY Buffalo, a démontré l'activité antioxydante intrinsèque d'ATH434 et sa capacité à redistribuer le fer labile en excès. Ces propriétés suggèrent un potentiel pour traiter des maladies neurodégénératives comme la maladie de Parkinson. ATH434 a également favorisé la production d'énergie dans les mitochondries via une voie moins susceptible de provoquer un stress oxydatif dans des cellules non stressées.
Le Dr. David Stamler, PDG d'Alterity, a souligné l'importance de ces résultats pour comprendre le potentiel d'ATH434 en tant que traitement modificateur de la maladie pour les troubles neurodégénératifs.
Alterity Therapeutics (NASDAQ: ATHE) präsentierte neue Daten zu ATH434 auf der Society for Neuroscience 2024 in Chicago. Das Poster mit dem Titel 'Potente antioxidative und mitochondrienprotektive Effekte von ATH434, einem neuartigen Inhibitor der α-Synuclein-Aggregation mit moderater Eisenbindung,' stellte die neuroprotektiven und mitochondrienprotektiven Eigenschaften von ATH434 vor, einschließlich der Reduzierung von Lipidschäden in zwei Modellen neuronaler Verletzungen.
Die Studie, geleitet von Dr. Daniel J. Kosman an der SUNY Buffalo, zeigte die intrinsische antioxidative Aktivität von ATH434 und seine Fähigkeit, überschüssiges labiles Eisen umzuverteilen. Diese Eigenschaften deuten auf ein Potenzial zur Behandlung neurodegenerativer Erkrankungen wie Parkinson hin. ATH434 förderte zudem die Energieproduktion in Mitochondrien über einen weniger anfälligen Weg zur Verursachung von oxidativem Stress in nicht gestressten Zellen.
Dr. David Stamler, CEO von Alterity, betonte die Wichtigkeit dieser Ergebnisse, um das Potenzial von ATH434 als krankheitsmodifizierende Therapie für neurodegenerative Erkrankungen zu verstehen.
- ATH434 demonstrated neuroprotective and mitochondrial protectant properties
- ATH434 showed intrinsic antioxidant activity, potentially beneficial for treating neurodegenerative diseases
- ATH434 reduced lipid damage in two distinct neuronal injury models
- ATH434 promoted energy production in mitochondria through a less oxidative stress-prone pathway
- None.
Insights
This new data on ATH434 provides valuable insights into its potential as a neuroprotective agent for neurodegenerative diseases. The study demonstrates ATH434's ability to reduce lipid damage in neuronal injury models and its inherent antioxidant properties. Key findings include:
- ATH434 shows efficacy as a lipid peroxidation protectant in both menadione-induced and hemin-induced oxidative stress models
- The compound promotes energy production in mitochondria through pathways less prone to causing oxidative stress
- ATH434 exhibits direct antioxidant capacity against potentially damaging charged molecules
These properties suggest ATH434 could protect vulnerable mitochondria in neurodegenerative conditions. While promising, it's important to note that these are preclinical findings and further research is needed to confirm therapeutic efficacy in humans. The compound's dual mechanism of action - redistributing excess labile iron and providing direct antioxidant effects - makes it an intriguing candidate for treating disorders like Parkinson's disease.
MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 were presented at the Society for Neuroscience 2024 in Chicago, USA.
The poster entitled, “Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of α-Synuclein Aggregation with Moderate Iron-binding Affinity,” demonstrates that the neuroprotective and mitochondrial protectant properties of ATH434 include reducing lipid damage in two distinct and disease-relevant neuronal injury models. Additional studies elucidate the inherent antioxidant properties and benefits of ATH434 in cellular energy usage. ATH434’s antioxidant properties were distinguished from those of another iron binding agent approved for treating iron overload. The study was run under the direction of Dr. Daniel J. Kosman, Distinguished Professor of Biochemistry at the State University of New York at Buffalo.
“These exciting new data further our understanding of ATH434’s potential as a disease modifying treatment for neurodegenerative diseases, including Parkinson’s disease and related disorders,” said, David Stamler, M.D., Chief Executive Officer of Alterity. “The study extended previous findings and demonstrated that ATH434 has intrinsic antioxidant activity. This is key as oxidative injury is an important contributor to the pathology of neurodegeneration. By addressing this injury in two different ways, both directly and by redistributing excess labile iron, ATH434 has excellent potential to treat this group of diseases. The ability of ATH434 to reduce damage to lipid membranes undergoing oxidative stress may augment its ability to slow disease progression. We are grateful for the continued valuable contributions from our collaborators in Dr. Kosman’s laboratory at SUNY-Buffalo.”
The study, authored by Dr. Danielle Bailey, investigated the efficacy of ATH434 and comparator agents as lipid peroxidation protectants using a menadione-induced model and a hemin-induced oxidative stress model in a neuronal cell line. In unstressed cells, ATH434 promoted energy production in mitochondria to a pathway less prone to causing oxidative stress. In-solution assays detailed the mechanisms underlying ATH434’s direct antioxidant capacity with respect to potentially damaging charged molecules. These combined properties can serve to protect vulnerable mitochondria in neurodegenerative diseases.
The poster presentation can be found on Alterity’s website here.
About ATH434
Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. ATH434 is currently being studied in two clinical trials: Study ATH434-201 is a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage MSA and Study ATH434-202 is an open-label Phase 2 Biomarker trial in patients with more advanced MSA. ATH434 has been granted Orphan drug designation for the treatment of MSA by the U.S. FDA and the European Commission.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
FAQ
What new data did Alterity Therapeutics (ATHE) present at the Society for Neuroscience 2024?
How does ATH434 potentially benefit patients with neurodegenerative diseases like Parkinson's?
What were the key findings of the ATH434 study presented by Alterity Therapeutics (ATHE)?
Who led the research on ATH434 presented by Alterity Therapeutics (ATHE) at the neuroscience meeting?
